The Rising Tide of Type 2 Diabetes: How Primary Care Can Improve Outcomes and Workload

5th March 2026

Type 2 diabetes is rising across England, with prevalence now at 7.0% of the adult population. For primary care teams, this means growing registers, more complex medication decisions, and increasing pressure on annual review capacity. A diabetes optimisation pharmacist helps practices respond to this challenge by creating a systematic approach to diabetes reviews and implementing NICE guidance safely and consistently. [1]

• The Scale of the Challenge
• What Does a Diabetes Optimisation Pharmacist Do?
• How Does Clinical Pharmacist-Led Optimisation Reduce Workload?
• Why is Modern Diabetes Management Focused on Cardio-Renal Protection?

Key Takeaways

• Specialist Role: This dedicated expert focuses on improving diabetes care across a PCN, driving improvements in both outcomes and efficiency.
• Guideline-Driven: Their work aligns with NICE guidelines to reduce variation and ensure evidence-based treatment, particularly around modern therapies that offer cardio-renal protection.
• Improves Outcomes: This role is key to improving HbA1c in primary care, ensuring cardio renal protection diabetes, and hitting QOF targets.
• Systematic Approach: They implement structured pathways for medication reviews, therapy escalation, and patient follow-up, creating a more resilient system.

The Scale of the Challenge

In England, while diabetes prevalence grows, national data shows that only 54.3% of patients receive all nine NICE-recommended care processes each year. [1] Closing this gap through effective diabetes annual review optimisation is one of the fastest ways to improve outcomes, ensure patient safety, and reduce the need for reactive, urgent care appointments. These gaps in care often lead to missed opportunities to intensify treatment, identify complications early, and reduce long-term cardiovascular risk.

What Does a Diabetes Optimisation Pharmacist Do?

A diabetes optimisation pharmacist is a specialist clinical pharmacist who helps primary care networks (PCNs) systematically improve care for patients with type 2 diabetes. By focusing on guideline-directed therapy and proactive case management, they help close gaps in care and improve patient outcomes. Central to this work is diabetes medication optimisation – ensuring every patient is on the right therapy at the right dose. This involves:

• Running structured medication reviews for complex patients.
• Identifying patients who need therapy escalation or optimisation.
• Implementing NICE guideline NG28 guidance, including new recommendations for SGLT2 inhibitors.
• Optimising blood pressure and lipid control to reduce cardiovascular risk.
• Ensuring the nine essential care processes are completed and acted upon.
• Reducing repeat GP appointments through proactive follow-up.

How Does Clinical Pharmacist-Led Optimisation Reduce Workload?

The primary goal of clinical pharmacist-led diabetes optimisation is to ensure every patient receives the right care at the right time, according to national standards. A structured clinical pharmacist-led diabetes optimisation pathway allows practices to standardise care and reduce variation across the register. This involves moving beyond simple annual reviews to a more dynamic and responsive model of care. A pharmacist diabetes clinic in primary care provides a dedicated setting for managing more complex patients. For example, a pharmacist diabetes clinic in primary care might prioritise patients with an HbA1c above 58 mmol/mol or those with evidence of kidney disease. By addressing diabetes medication optimisation and monitoring in a single, structured appointment, clinical pharmacists can prevent multiple follow-up GP reviews.

Why is Modern Diabetes Management Focused on Cardio-Renal Protection?

Effective diabetes management is about more than just controlling blood glucose. The modern approach, in the latest NICE guideline NG28, focuses on holistic assessments of patient risk, particularly cardiovascular and renal-health.

NICE guidance now recommends SGLT2 inhibitors earlier in the treatment pathway for many patients. Specifically to reduce the risk of complications like heart failure and chronic kidney disease. A clinical pharmacist can ensure that eligible patients are identified and offered these protective therapies through dedicated clinical pharmacist support within primary care.

“Empowering a clinical pharmacist to lead on diabetes optimisation is one of the most effective ways a PCN can drive meaningful improvements in patient care. It moves the focus from reactive treatment to proactive, guideline-led management that prevents complications and improves lives.”

Adeem Azhar, Co-Founder and Chief Executive Officer – Core Prescribing Solutions

Frequently Asked Questions

What is a diabetes optimisation pharmacist? This is a clinical pharmacist with a special interest and enhanced skills in diabetes management who works with PCNs to improve care quality, safety, and outcomes for patients with diabetes.

How does this role differ from a general practice pharmacist? While a general practice pharmacist manages a wide range of conditions, this specialist role focuses exclusively on the diabetes patient cohort, allowing for a greater depth of expertise and more systematic quality improvement.

What are the benefits for a PCN? The main benefits include improved QOF achievement, reduced variation in care, better patient outcomes (e.g., lower HbA1c), and increased practice capacity as the pharmacist takes on complex reviews.

How does this align with Structured Medication Reviews (SMRs)? This work is a core part of proactive Structured Medication Reviews (SMRs), as described in NHS England guidance on SMRs. Within a pharmacist diabetes clinic in primary care, the clinical pharmacist will conduct Level 3 medication reviews focused on diabetes therapy.

[1] Diabetes profile: statistical commentary, March 2025 – GOV.UK

What are the 4 principles of medicines optimisation?

11th February 2026

The 4 principles of medicines optimisation offer a person-centred way to improve patient outcomes and reduce system waste. For PCNs, applying this framework is the most effective way to manage rising polypharmacy, improve safety, and make prescribing sustainable across primary care.

• What are the 4 principles of medicines optimisation?
• How does understanding the patient’s experience improve outcomes?
• Why does evidence-based prescribing matter long-term?
• How do you make medicines use as safe as possible?
• How do you embed these principles into routine practice?

Key Takeaways

• Person-centred care: This framework focuses on shared decision-making, not compliance, by prioritising the patient’s experience.
• Evidence and safety: The principles require clinicians to balance guidelines with patient-specific factors, particularly for high-risk therapies.
• System integration: The framework must be embedded into routine workflows and linked to long-term condition (LTC ) management.
• Workforce strategy: Clinical Pharmacists and Pharmacy Technicians working together is the most effective model for delivering on these principles.

What are the 4 principles of medicines optimisation?

The four principles, set out by the Royal Pharmaceutical Society and reflected in the NICE guideline (NG5), provide a framework for ensuring patients get the best outcomes from their medicines. They are straightforward in theory. The challenge is applying them consistently in a busy primary care setting.

Principle	Focus
1. Understand the patient’s experience	Shared decision-making and adherence
2. Evidence-based choice of medicines	Right medicine, right patient, right time
3. Make medicines use as safe as possible	Harm reduction across the medicines pathway
4. Make it part of routine practice	Embedding into daily workflows

How does understanding the patient’s experience improve outcomes?

This first principle focuses on shared decision-making. The goal is to understand what matters to the patient – how medicines fit into their life, what side effects they experience, and what barriers affect adherence. This is not about checking compliance; it is about listening.

In practice, this often reveals adherence issues or side effects that never surface in routine repeat prescribing.

For PCNs, Structured medication reviews (SMRs) are the primary vehicle for these conversations. A well-conducted SMR creates the time that transactional reviews do not. Without it, non-adherence and avoidable prescribing cascades continue unchecked.

Why does evidence-based prescribing matter long-term?

This second principle requires clinicians to balance national guidelines with individual factors such as frailty, renal function, and comorbidities. It is not about rigid guideline adherence – it is about intelligent application.

A common failure in primary care is long-term medicines that were appropriate at initiation but never reassessed. For example, medicines started years earlier for short-term benefit are often continued without review, increasing risk without clear ongoing value. This drives unnecessary polypharmacy and increased monitoring burden. Clinical Pharmacists are central to addressing this within PCNs, where they can see the full clinical picture.

The four principles give us a clear framework, but they only work when applied by a team with the time and expertise to see the whole picture. An integrated pharmacy team turns principles into practice.

Adeem Azhar, Co-Founder and Chief Executive Officer – Core Prescribing Solutions

How do you make medicines use as safe as possible?

Safety underpins all four of these medicines optimisation principles and is where poor systems cause the most patient harm. This third principle targets harm reduction across the entire pathway – prescribing, dispensing, monitoring, and administration. Key risks in primary care include high-risk medicines (anticoagulants, opioids, insulin), inadequate monitoring, and poor reconciliation after hospital discharge.

Pharmacy Technicians add significant value here by managing data quality, patient recalls, and medicines reconciliation. This frees Clinical Pharmacists to focus on complex clinical decisions rather than chasing blood tests.

How do you embed these principles into routine practice?

This fourth principle is the one most practices struggle with. This approach only delivers sustained value when it is part of daily workflows, not a separate project. It requires clear role definitions, consistent processes, and integration with long-term condition (LTC) reviews and care planning.

In high-performing PCNs, this framework is built into SMR clinics and supported by a stable pharmacy workforce. Without this structure, practices firefight medicines issues rather than prevent them.

FAQs

Clinical use of magnesium: What Pharmacists and GPs Should Know

19th January 2026

Magnesium is widely used in clinical practice to treat hypomagnesaemia, a condition frequently overlooked in primary care, particularly in patients on long-term PPIs or diuretics. Magnesium deficiency is usually defined as serum magnesium below 0.7 mmol/L, though local lab ranges vary slightly. Clinical pharmacists and GPs should know when to test, how to treat, and which drug interactions require magnesium monitoring in primary care to reduce the risk of arrhythmias and digoxin toxicity.

• When should magnesium levels be tested in primary care?
• Which medications cause hypomagnesaemia?
• How is hypomagnesaemia classified and managed?
• What are the key drug interactions with low magnesium?
• What monitoring is required during magnesium replacement?
• A simple approach to magnesium monitoring in primary care

Key Takeaways

• Check magnesium before and during long-term PPI use, especially with digoxin or diuretics (MHRA)
• Think magnesium if hypokalaemia or hypocalcaemia won’t correct
• Treat mild cases orally (10-24 mmol/day in divided doses); escalate severe or symptomatic cases for IV
• Review the cause (PPI necessity, diuretic type/dose, renal function) to prevent recurrence

When should magnesium levels be tested in primary care?

Magnesium testing should be considered in patients with symptoms such as muscle cramps, fatigue, or weakness, and routinely in those on medications associated with hypomagnesaemia.

The MHRA advises healthcare professionals to “consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment”, particularly for patients also taking digoxin or diuretics. PPI-induced hypomagnesaemia is a recognised risk, especially after 12 months of continuous use.

Test magnesium when:

• Starting long-term PPI therapy (baseline)
• Reviewing patients on PPIs for more than 12 months
• Hypokalaemia or hypocalcaemia is not responding to replacement
• Patients on loop or thiazide diuretics report muscle cramps or fatigue
• Digoxin toxicity is suspected

Which medications cause hypomagnesaemia?

Several commonly prescribed medications can lower magnesium levels, making medication review important for identifying at-risk patients.

Medication Class	Examples	Mechanism
Proton pump inhibitors	Omeprazole, lansoprazole	Impaired intestinal absorption
Loop diuretics	Furosemide, bumetanide	Increased renal excretion
Thiazide diuretics	Bendroflumethiazide, indapamide	Increased renal excretion
Aminoglycosides	Gentamicin	Renal magnesium wasting
Immunosuppressants	Tacrolimus, ciclosporin	Renal tubular effects

For patients on long-term PPIs, consider whether continued use is clinically necessary. Where appropriate, H2 receptor antagonists such as famotidine may be considered.

How is hypomagnesaemia classified and managed?

Mild magnesium deficiency (0.5-0.7 mmol/L) is often asymptomatic or causes non-specific symptoms, while severe deficiency (<0.5 mmol/L) can cause tetany, seizures, and arrhythmias.

Mild hypomagnesaemia is managed with oral magnesium replacement therapy at 10-24 mmol/day in divided doses. Licensed options include magnesium aspartate sachets (10 mmol), magnesium citrate tablets (4 mmol), and magnesium glycerophosphate. Start low and increase gradually to minimise diarrhoea.

Severe hypomagnesaemia requires IV magnesium sulphate in hospital, with ECG and blood pressure monitoring.

Treatment should continue for 1-2 days after levels normalise, as intracellular stores take longer to replenish.

What are the key drug interactions with low magnesium?

Low magnesium increases the risk of magnesium and digoxin toxicity by enhancing myocardial sensitivity. Patients taking digoxin alongside PPIs or diuretics should have magnesium monitored, particularly if symptoms of toxicity occur.

Hypomagnesaemia also potentiates QT-prolonging drugs, increasing arrhythmia risk. This is particularly relevant with antiarrhythmics, some antipsychotics, macrolides, and fluoroquinolones.

Magnesium is easy to overlook in routine practice, but for patients on long-term PPIs or diuretics, proactive monitoring can prevent serious complications. A simple blood test and medication review can make a real difference.

Adeem Azhar, Co-Founder and Chief Executive Officer – Core Prescribing Solutions

What monitoring is required during magnesium replacement?

Magnesium monitoring in primary care should focus on confirming response to replacement, identifying ongoing causes such as continued PPI use or renal losses, and preventing recurrence through medication review and deprescribing where appropriate.

• Confirming response to replacement
• Identifying ongoing causes such as continued PPI use or renal losses
• Preventing recurrence through medication review and deprescribing where appropriate

A simple approach to magnesium monitoring in primary care

• Baseline: Check magnesium before starting long-term PPI therapy
• At-risk patients: Repeat periodically in those on PPIs, diuretics, or digoxin
• After replacement: Recheck at 7 days, then at 1-3 months
• Ongoing risk: Review annually if the underlying cause persists

Recheck serum magnesium 7 days after starting oral treatment and again at 1-3 months depending on the cause. Monitor calcium and potassium, as deficiencies often coexist.

In patients with renal impairment (CKD 4-5, AKI, or dialysis), seek specialist advice before initiating replacement due to hypermagnesaemia risk.

FAQs

For patients asking about over-the-counter supplements, including magnesium glycinate, see our guide to magnesium glycinate. For clinical guidance, refer to NHS SPS and the MHRA Drug Safety Update.

A Practical Guide to Structured Medication Reviews (SMR) for Long-Term Conditions

9th January 2026

Structured medication reviews (SMRs) are a structured, person-centred review of medicines for people living with long-term conditions in primary care. They move clinicians beyond routine prescription checks and into meaningful conversations about safety, outcomes and what matters most to patients. As medicines accumulate over time, the risk of treatment burden and medicines-related harm increases without regular review. SMRs provide a clear, repeatable framework to manage this safely and consistently across Primary Care Networks (PCNs).

Why reviews matter in long-term condition care
Who should be prioritised for an SMR?
The structured medication review checklist
Who delivers SMRs?

Key takeaways

• Structured medication reviews for long term conditions are not routine reviews – they are in-depth clinical consultations, not administrative checks
• Risk matters more than volume – patients with complex needs and polypharmacy benefit most
• Clear governance enables impact – pharmacist prescribers prevent work drifting back to GPs

Why reviews matter in long-term condition care

Structured medication reviews support effective long-term condition management in primary care by enabling safer prescribing for complex patients. People with chronic illness are more likely to experience prescribing cascades and cumulative side effects.

In practice, structured medication reviews for long term conditions provide a clinical framework for reviewing complex prescribing in people with multiple long-term conditions. A focused structured medication review LTC creates protected time to reassess treatment rather than continuing historic prescribing by default.

A structured medication review is only valuable if it leads to real clinical decisions. When reviews focus on risk, outcomes and patient priorities, they reduce harm and prevent work recycling back to already stretched GP teams.

Adeem Azhar, Co-Founder and Chief Executive Officer – Core Prescribing Solutions

Who should be prioritised for an SMR?

SMRs should be targeted based on clinical risk rather than age alone. A targeted polypharmacy medication review is most beneficial for patients who:

• Live with multiple long-term conditions
• Take several regular medicines with high treatment burden
• Are at increased risk of harm, such as falls or renal impairment
• Use high-risk medicines, including anticoagulants or lithium
• Have had a recent medicines-related hospital admission

This approach helps GP practices and PCNs focus capacity where it delivers the greatest population benefit.

The structured medication review checklist

To ensure safety and consistency, an SMR GP practice should follow a clear clinical pathway. Many teams use a structured medication review checklist to guide consultations:

• Patient priorities
• Indication and benefit
• Safety and monitoring
• Adherence
• Deprescribing opportunities

This aligns with NICE guidance on medicines optimisation and supports clear clinical decisions.

Safety and deprescribing in long-term conditions

Polypharmacy is common in chronic illness, but more medicines do not always mean better outcomes. A structured polypharmacy medication review helps reduce cumulative risk, simplify regimens and plan deprescribing safely, improving adherence and reducing avoidable harm.

Who delivers SMRs?

Structured medication reviews can be delivered by GPs or clinical pharmacists. In many practices, pharmacist prescribers add the greatest value by making real-time prescribing decisions without unnecessary hand-offs. Clear governance ensures reviews translate into action rather than additional GP workload.

FAQs

Hypothyroidism (Underactive thyroid): Symptoms, Causes and Treatment Explained

9th January 2026

Page last reviewed: 1st May 2026

Hypothyroidism, also known as an under active thyroid, occurs when the thyroid gland does not produce enough thyroid hormones. Hypothyroidism is one of the most common long-term conditions managed in primary care, requiring ongoing monitoring and medication titration. The condition usually develops gradually, which is why underactive thyroid symptoms are often overlooked or attributed to other causes.

Hypothyroidism symptoms
Causes of an underactive thyroid
Diagnosis and thyroid blood tests
What does a low T4 result mean?
Treatment for hypothyroidism
Diet and hypothyroidism
Hypothyroidism in women and men
Eyes and thyroid disease
Hypothyroidism and weight
FAQs

Key takeaways

• Symptoms develop slowly, meaning the condition is often overlooked
• Levothyroxine is effective, but correct dosing, timing and absorption are critical
• Untreated disease increases cardiovascular risk, making long-term monitoring essential

What is Hypothyroidism?

Hypothyroidism, or an underactive thyroid, is a common medical condition where the thyroid gland in the neck does not produce enough essential hormones. These hormones are crucial for regulating the body’s metabolism, energy levels, heart rate, and temperature. When hormone levels are too low, many bodily functions slow down, leading to a range of symptoms.

What are the symptoms of hypothyroidism?

Hypothyroidism symptoms usually build up over time rather than appearing suddenly.

Common symptoms of underactive thyroid include:

• Persistent tiredness and low energy
• Feeling cold
• Weight gain
• Constipation
• Low mood or depression
• Poor concentration or “brain fog”
• Dry skin, brittle hair or hair loss
• Hoarse voice

If left untreated, this thyroid deficiency is associated with raised cholesterol levels, increasing long-term cardiovascular risk.

What causes an underactive thyroid?

Autoimmune conditions are the leading cause of an underactive thyroid.

Key causes include:

• Autoimmune thyroiditis (Hashimoto’s disease)
• Previous thyroid surgery or radioactive iodine treatment
• Certain medicines, particularly lithium and amiodarone
• Postpartum thyroiditis
• Iodine deficiency, now uncommon in the UK
• Identifying the cause helps guide follow-up and long-term management.

How is hypothyroidism diagnosed?

Diagnosis is based on thyroid blood tests, usually measuring TSH and free T4. A raised TSH with a low free T4 confirms primary disease and guides treatment decisions, in line with national guidance from the NICE Clinical Knowledge Summaries on hypothyroidism.

What does a low T4 result mean?

A low T4 level usually indicates an underactive thyroid. When T4 levels fall, metabolism slows, leading to symptoms such as fatigue, weight gain and cold sensitivity. Results are interpreted alongside TSH to confirm the diagnosis.

How is hypothyroidism treated?

Hypothyroidism treatment usually involves long-term hormone replacement. Levothyroxine replaces the hormone the thyroid gland is not producing and remains the standard first-line option.

Key points for patients:

• Symptom improvement can take several weeks
• Doses often need adjustment early on
• Regular blood tests are essential

Because timing and interactions affect absorption, taking levothyroxine correctly is an important part of effective treatment. Once stable, thyroid function is usually checked yearly, in line with national guidance, with blood tests typically repeated 6-8 weeks after dose changes – an important part of high-risk medication monitoring in primary care. If symptoms persist despite blood results in range, a structured medication review for long-term conditions can help identify issues with dosing, interactions or adherence. Liothyronine (T3) is generally reserved for specialist care.

Can diet affect hypothyroidism treatment?

There is no specific diet that treats this condition, but diet can affect how well medication works.

Practical advice includes:

• Take levothyroxine on an empty stomach at the same time each day
• Avoid taking it close to calcium or iron supplements
• Soya and caffeine can reduce absorption if taken too near the dose
• Avoid iodine-rich supplements such as kelp unless advised

A balanced diet is sufficient for most people.

Does hypothyroidism affect women and men differently?

Women are more likely to be affected, with symptoms sometimes overlapping with perimenopause, including fatigue, low mood, heavy periods and fertility problems. During pregnancy, careful monitoring is important.

The condition is less common in men and may be diagnosed later. Symptoms can include reduced libido, erectile dysfunction, fatigue and reduced physical performance. Further patient support and resources are available from Thyroid UK.

Can hypothyroidism cause eye problems?

Eye disease is more strongly linked to hyperthyroidism, but people with hypothyroidism may experience dry or irritated eyes. New symptoms such as eye bulging, double vision or visual loss require urgent assessment.

How does hypothyroidism affect weight?

Weight gain is common, although it is often modest and partly related to fluid retention. Unintentional weight loss is not typical and should prompt investigation for other causes.

“Hypothyroidism is a condition where small gaps in diagnosis, treatment or monitoring can quietly create long-term risk. Getting it right means consistent follow-ups and ensuring medicines titrated as and when needed based on clinical need.”

Adeem Azhar, Co-Founder and Chief Executive Officer – Core Prescribing Solutions

FAQs

How Independent Prescribing Clinics in Primary Care Improve Long-Term Condition Outcomes 

22nd December 2025

Independent prescribing clinics in primary care are structured, medicines-led clinics where qualified prescribers manage long-term conditions through planned reviews, prescribing, medicines optimisation, monitoring and follow-up within agreed clinical pathways.

Their purpose is to create predictable capacity for long-term condition care, improve prescribing safety and reduce reliance on reactive GP appointments. They are particularly effective for conditions such as hypertension, diabetes, asthma, chronic obstructive pulmonary disease (COPD) and cardiovascular disease.

Key takeaways

• Independent prescribing clinics move long-term condition care from reactive GP follow-up into planned, medicines-led clinics
• Structured clinics improve medicines optimisation, monitoring and prescribing safety
• When properly integrated, they reduce repeat appointments and release GP capacity without increasing clinical risk

What independent prescribing clinics look like in practice

Independent prescribing clinics are not generic review appointments. They are structured clinics delivered by prescribers with defined responsibility for medicines optimisation, follow-up and monitoring within clear clinical pathways.

In primary care, these clinics are commonly delivered by an independent prescribing pharmacist in primary care, embedded within the wider practice or Primary Care Network (PCN) team and supported by established clinical pharmacist support. When designed well, independent prescribing clinics in primary care provide planned, repeatable capacity for medicines-led long-term condition care rather than ad hoc prescribing support or informal GP handovers.

Why long-term condition review clinics matter

Patients with long-term conditions require proactive, ongoing review to prevent deterioration, polypharmacy and avoidable escalation. When reviews are delayed or fragmented, practices see repeated appointments, rising prescription queries and increasing clinical risk.

Well-designed long-term condition review clinics separate medicines-led care from acute GP demand. This allows patients to be reviewed consistently while maintaining continuity and clinical oversight. This approach aligns with national guidance from the National Institute for Health and Care Excellence, which emphasises regular review, medicines optimisation and monitoring as core components of long-term condition care.

Improving outcomes through medicines optimisation clinics

Prescribing for long-term conditions requires careful titration, monitoring and follow-up. Independent prescribing clinics support this by focusing on medicines optimisation rather than reactive prescribing.

In practice, medicines optimisation clinics allow prescribers to adjust treatment earlier, address non-adherence and reduce inappropriate medicines. PCNs using structured medicines-led clinics often report fewer repeat prescription queries and more stable long-term condition control, reflecting the value of embedded medicines optimisation services that focus on outcomes rather than throughput.

Prescribing safety clinics and medicines monitoring clinics

Medicines safety is central to effective long-term condition management, particularly for patients with multimorbidity or complex regimens.

Independent prescribing clinics frequently operate as prescribing safety clinics, with protected time to monitor high-risk medicines, review interactions and ensure appropriate follow-up. Framing this work explicitly as prescribing safety clinicsstrengthens prescribing governance, helping practices prioritise risk reduction alongside access improvements.

This is reinforced through structured medicines monitoring clinics, which improve compliance with blood tests, observations and documentation. Embedding monitoring into routine clinic workflows supports safer prescribing and reduces downstream administrative burden.

The role of the clinical pharmacist prescriber

Many independent prescribing clinics are delivered by a clinical pharmacist prescriber, bringing specialist medicines expertise into routine long-term condition care.

By managing medicines-led reviews, follow-up and optimisation, clinical pharmacist prescribers reduce repeat GP consultations and prescription queries. When embedded within practice teams and aligned to wider ARRS workforce support, this model improves access while maintaining clear escalation routes and strong clinical governance.

Why integration matters more than headcount

The success of independent prescribing clinics depends less on workforce numbers and more on how roles are deployed.

In many areas, prescribing roles are funded through the Additional Roles Reimbursement Scheme (ARRS). Outcomes improve when clinics are embedded into practice workflows, aligned to defined objectives and supported by strong governance. When integrated properly, independent prescribing clinics in primary care complement wider workforce planning rather than operating as standalone activity.

Poor integration, by contrast, leads to duplication, under-utilisation and limited impact on GP workload.

FAQs

Hypertension case finding in primary care- A Practical NHS Pathway

15th December 2025

Hypertension remains one of the most common and preventable causes of cardiovascular disease in England. Despite clear guidance and effective treatments, an estimated 30 percent of adults with hypertension remain undiagnosed, leaving many people at avoidable risk of heart attack, stroke, and long-term complications.

Hypertension case finding in primary care exists to close this gap. It brings together general practice, Primary Care Networks (PCNs), and community pharmacy to identify people earlier, confirm diagnosis accurately, and intervene before harm occurs.

However, screening alone does not improve outcomes. Hypertension case finding only delivers value when primary care owns a clear, end-to-end pathway that consistently converts blood pressure checks into diagnosis, optimisation, and sustained control.

This article outlines a practical, NHS-aligned approach to hypertension case finding in primary care, with a focus on governance, workforce, and measurable outcomes.

Key takeaways

• Hypertension case finding is a primary care pathway, not a standalone screening activity
• Community pharmacies expand access, but diagnosis and optimisation remain the responsibility of primary care
• NICE NG136 confirmation thresholds must be embedded using ambulatory or home monitoring
• The biggest risk is not missing raised blood pressure, but failing to act on it consistently
• PCNs that build structured follow-up and medicines optimisation into pathways achieve better outcomes, not just higher detection rates

What hypertension case finding means in primary care

In primary care, hypertension case finding refers to the proactive identification of people with undiagnosed high blood pressure, followed by structured confirmation, diagnosis, treatment, and review.

This approach goes beyond opportunistic readings. Effective pathways ensure that raised blood pressure leads to timely confirmation, accurate coding, and treatment initiation. In practice, this forms a hypertension pathway primary care teams can rely on rather than a series of disconnected activities.

While multiple settings contribute to detection, primary care retains clinical accountability for diagnosis, prescribing, and long-term management. Without this ownership, blood pressure case finding risks becoming an activity measure rather than a population health intervention.

This pathway-led approach underpins wider hypertension management and aligns with how practices approach hypertension case finding in primary care.

The role of community pharmacy

The NHS Community Pharmacy Blood Pressure Check Service has expanded access to blood pressure checks, particularly for people who rarely attend routine GP appointments.

Community pharmacies support hypertension case finding by providing accessible blood pressure checks, identifying raised readings, and, where appropriate, offering ambulatory blood pressure monitoring. Their role is to extend reach and capacity, feeding timely information back into primary care–led pathways rather than operating as an alternative to them.

For practices and PCNs, pharmacies act as capacity multipliers rather than replacements. When integrated into a clearly defined pathway, they improve access and reduce pressure on appointments. Where pathways and ownership are unclear, they can unintentionally increase administrative burden and clinical risk.

Primary care retains responsibility for confirmation, diagnosis, and ongoing management, in line with NICE Hypertension in adults guideline (NG136), which sets expectations for diagnostic thresholds, monitoring, and treatment optimisation.

Confirmation and diagnosis – embedding NICE NG136

NICE NG136 provides a clear framework for confirming hypertension, yet this remains one of the most common failure points.

These confirmation steps are defined in NICE NG136 hypertension guidance and should be embedded consistently across primary care pathways.

Getting this stage right is fundamental to safe and timely hypertension diagnosis primary care, particularly where multiple clinicians and settings are involved in confirmation and follow-up.

Key principles include:

• Clinic readings of 140/90 mmHg or higher require confirmation
• Ambulatory blood pressure monitoring ABPM is the preferred diagnostic method
• Home blood pressure monitoring HBPM is appropriate when ABPM is unsuitable
• Diagnosis is confirmed using average ABPM or HBPM readings

Embedding these steps consistently is essential for safe hypertension diagnosis primary care pathways. Primary care teams must ensure confirmation is timely, results are reviewed by the right clinician, and patients are not left in prolonged monitoring states without action.

This stage benefits significantly from structured clinical pharmacist support, particularly in practices managing high volumes of ABPM and HBPM results.

Where case finding often breaks down

Despite national services and clear guidance, similar issues occur across systems:

• Raised readings are recorded but not followed up
• ABPM is requested but not completed
• Results return without clear ownership
• Patients fall between pharmacy, practice, and PCN workflows
• Treatment is initiated but not optimised

When hypertension case finding is not supported by a clear pathway, the risk shifts from under-detection to missed diagnosis and poor follow-up. This leads to avoidable cardiovascular risk and unnecessary workload across the system.

Why identifying undiagnosed hypertension matters

Undiagnosed hypertension carries significant consequences beyond individual patient risk. Persistently raised blood pressure is a major contributor to avoidable stroke, myocardial infarction, heart failure, and progressive kidney disease, all of which place long-term demand on acute, community, and social care services.

Earlier identification through structured hypertension case finding allows primary care to intervene before these complications occur. For the wider healthcare economy, this means fewer emergency admissions, reduced long-term prescribing burden, and improved population health outcomes. From a system perspective, the value of diagnosing hypertension early lies not only in improved patient outcomes, but in preventing downstream costs that are far more complex and expensive to manage.

From detection to blood pressure optimisation

The greatest clinical and system value of hypertension case finding in primary care comes after diagnosis.

This is where medicines optimisation hypertension activity becomes critical, ensuring treatment decisions are reviewed, adjusted, and aligned to NICE guidance rather than left static after diagnosis.

Effective pathways include structured medication reviews, stepwise titration aligned to NICE guidance, routine use of home monitoring, and clear recall and review processes. This is where medicines optimisation hypertension activity directly improves outcomes rather than simply increasing detection figures.

Clinical pharmacists and pharmacy technicians play a central role in medicines optimisation, adherence support, and safe titration. This is where medicines optimisation support helps practices translate detection into sustained blood pressure control while reducing GP workload.

Governance and delivery at PCN level

For PCNs and system leaders, hypertension pathway primary care delivery should be viewed as a population health intervention rather than a collection of services.

Successful delivery depends on clear ownership at each stage, defined handovers between pharmacy and practice, consistent coding, and workforce models designed for long-term value.

At PCN level, consistent medicines optimisation hypertension processes help reduce unwarranted variation between practices while improving long-term blood pressure control across populations.

When Additional Roles Reimbursement Scheme (ARRS) funding is deployed strategically, supported by models such as ARRS workforce support for PCNs, networks can scale hypertension case finding safely and effectively. Access to consistent clinical pharmacist support services enables PCNs to move from opportunistic detection to reliable diagnosis and optimisation at scale.

Clinical insight

Hypertension case finding only delivers value when primary care owns the full pathway. Identifying raised blood pressure is step one. Diagnosis, optimisation, and follow-up are where patient outcomes actually change.

Adeem Azhar, Co-Founder and Chief Executive Officer – Core Prescribing Solutions

Summary

Hypertension case finding in primary care represents a major opportunity to reduce avoidable cardiovascular disease across the NHS. Its success depends not on the number of checks completed, but on the strength of the pathway that follows.

When confirmation, diagnosis, and optimisation are owned by primary care, supported by community pharmacy and PCN-level workforce planning, hypertension case finding becomes a scalable, outcome-focused intervention that delivers long-term value for patients and the system.

A Complete Guide to Delivering a NICE-Aligned Lipid management service in Primary Care

11th December 2025

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality in the NHS. Primary care teams carry a significant proportion of the prevention workload, particularly within long-term conditions management. As prevalence continues to rise, PCNs (Primary Care Networks) and GP practices need structured, data-driven approaches to lipid optimisation that support earlier intervention and reduce population-level risk.

• Why Lipid Management Matters for Cardiovascular Disease Prevention
• Understanding NICE Guidance for High Cholesterol Treatment
• Identifying High-Risk Patients Through Data-driven case finding
• Delivering a Structured Lipid Review Pathway in Primary Care
• How PCNs Can Implement a NICE-Aligned Lipid management service

A high-quality lipid management service improves outcomes when it is embedded into routine pathways, supported by Clinical Pharmacists and pharmacy technicians, and aligned with national guidance. This article outlines a clear, practical framework for PCN and practice teams, based on evidence, workforce capability, and operational best practice.

Key Takeaways

• A NICE-aligned lipid pathway provides consistency, faster clinical decisions, and measurable improvements in cardiovascular risk reduction.
• Clinical Pharmacist-led clinics form a core component of scalable lipid optimisation within primary care to help achieve QOF indicators.
• Data-driven case finding enables proactive identification of high-risk patients using tools such as QRISK and population health stratification.
• Structured medication reviews ensure safety, governance, and optimisation at each stage of the pathway.
• PCNs that adopt a pathway-based model gain long-term value through consistent processes, reduced unwarranted variation, and better performance against QOF and IIF indicators.

Why Lipid Management Matters for Cardiovascular Disease Prevention

Cardiovascular disease prevention depends heavily on effective identification and management of dyslipidaemia. National guidance, including NICE NG238 on lipid modification, outlines clear thresholds for intervention, monitoring, and escalation.

A strong lipid management service:

• Supports PCN responsibilities for population health and prevention.
• Reduces unplanned care demand by preventing avoidable cardiovascular events.
• Aligns with wider NHS ambitions for improved outcomes in high-burden long-term conditions.

For primary care teams, integrating lipid optimisation into routine clinical work is essential for achieving system-level targets and securing Impact and Investment Fund (IIF) achievements and help achieving QOF indicators.

Understanding NICE Guidance for High Cholesterol Treatment

Clinicians and PCN leaders need a clear interpretation of the national lipid pathway to ensure consistency across practices. The NHS England and Accelerated Access Collaborative summary provides practical clarity on treatment order, thresholds, and escalation.

Key themes include:

• Prioritising high-intensity statins (e.g., Atorvastatin) as first-line therapy.
• Rapid escalation: Moving quickly to Ezetimibe and then considering injectable therapies like Inclisiran or Bempedoic Acid when LDL-C targets are not met.
• Using validated risk tools for decision-making.
• Ensuring structured follow-up for monitoring and adherence.

A standardised approach ensures patients receive the right treatment at the right time, rather than getting stuck on suboptimal therapy.

Identifying High-Risk Patients Through Data-driven case finding

High-quality lipid optimisation relies on identifying the correct patients at scale. Data-driven case finding allows PCNs to proactively target those at greatest cardiovascular risk.

Effective approaches include:

• Using QRISK tools to stratify risk across the registered population.
• Employing population health management dashboards (such as Ardens or APEX).
• Running targeted searches for patients with unmanaged LDL-C, missed annual reviews, or high-risk co-morbidities.
• Reviewing variation in prescribing to ensure adherence to NICE-aligned pathways.
• Patient education

These methods help reduce health inequalities and ensure consistent access to preventive care.

Delivering a Structured Lipid Review Pathway in Primary Care

A robust lipid management service is most effective when the pathway is delivered through Clinical Pharmacist-led clinics. Clinical Pharmacists and Pharmacy Technicians bring specialist knowledge in medicines optimisation, risk stratification, and patient education.

A structured pathway typically includes:

• Initial lipid assessment and cardiovascular risk calculation.
• Review of current therapy, adherence, and contraindications.
• Evidence-based initiation or escalation in line with NICE guidance.
• Follow-up testing and monitoring.
• Coordination with GPs, nurses and practice teams for shared decision-making.

Structured medication reviews support medicines safety, ensure governance, and help align decisions with each patient’s needs, co-morbidities, and long-term condition profile.

How PCNs Can Implement a NICE-Aligned Lipid management service

Primary Care Networks can integrate a complete lipid pathway by combining workforce expertise, clinical governance, and operational support. Many PCNs choose to partner with organisations delivering primary care support services to enhance capacity and standardise delivery.

Key steps include:

1. Workforce Planning
Ensure sufficient Clinical Pharmacist and Pharmacy Technician capacity to run recurring clinics, undertake reviews, and support data-led patient recalls.

2. Data and Governance
Establish clear protocols, escalation pathways, and monitoring intervals. Use standard templates that align with NICE NG238 to ensure accurate coding for QOF.

3. Patient Communication and Follow-Up
Adopt structured recall processes and ensure continuity across the pathway.

4. Measurement and Continuous Improvement
Track achievement of lipid-level targets, time to optimisation, and overall impact on cardiovascular risk within the PCN population.

Leadership Perspective

A consistent, NICE-aligned lipid pathway allows PCNs to deliver meaningful improvements in cardiovascular prevention. When supported by the right clinical workforce and strong governance, these pathways offer long-term value for practices-ensuring QOF achievement while delivering measurable benefits for patients.

Adeem Azhar, Co-Founder and Chief Executive Officer – Core Prescribing Solutions

Frequently Asked Questions

Summary

Delivering a high-quality lipid management service requires a combination of clinical expertise, governance, data-driven workflows, and workforce capacity. When aligned with NICE guidance and embedded within wider long-term condition pathways, PCNs gain a model that supports prevention, improves outcomes, and delivers long-term value for patients and the NHS.Core Prescribing Solutions can partner with PCNs and practices nationwide to deliver a bespoke lipid management service.

LTC and Long-Term Condition Management in Primary Care

13th November 2025

Long-term condition (LTC) management in primary care is one of the most significant operational pressures facing GP practices and Primary Care Networks (PCNs). Rising multimorbidity, an ageing population, and growing clinical complexity continue to widen the capacity gap. Hypertension affects over one in four adults, type 2 diabetes prevalence has doubled in the past 15 years, and respiratory LTCs such as chronic obstructive pulmonary disease (COPD) and asthmacontribute heavily to avoidable workload across the NHS.

Clinical Pharmacists and Pharmacy Technicians working in general practice, supported through the Core Prescribing Solutions Clinical Pharmacist and Pharmacy Technician support in General Practice models, offer a structured, clinically robust way for practices to meet this rising demand. They deliver recall frameworks, evidence-based reviews, and medicines optimisation that improve outcomes while reducing GP workload. This collaborative approach is now essential for delivering safe, consistent, and high-quality LTC and long-term condition management in primary care.

This article outlines best practice for LTC management, aligned with NICE guidance and supported by measurable benefits for PCNs, practices, and patients.

Key Takeaways

• Structured LTC pathways improve safety, increase control rates, and reduce clinical risk.
• Hypertension, type 2 diabetes, lipid disorders, asthma, and COPD represent the greatest LTC pressures in primary care.
• Clinical Pharmacists lead optimisation, clinical decision-making, and high-risk medicines oversight.
• Pharmacy Technicians strengthen recall, data accuracy, inhaler technique support, and workflow efficiency.
• Standardised pathways improve QOF performance and deliver long-term value for PCNs and practices.

Hypertension Management in Primary Care

Hypertension remains a major contributor to cardiovascular disease. More than five million people in the UK are estimated to have undiagnosed hypertension, making structured identification and follow-up essential. NICE NG136provides guidance on accurate diagnosis using Home Blood Pressure Monitoring (HBPM), appropriate clinic versus home targets, and stepwise titration.

Clinical Pharmacists lead hypertension clinics, manage titration in line with NG136, and review lifestyle and adherence factors that influence control. Pharmacy Technicians support the pathway by coordinating HBPM processes, coding readings accurately, managing recall, and maintaining data quality.

A structured hypertension management model increases diagnosis rates, improves control across cohorts, and reduces variation that often emerges when practices rely solely on opportunistic reviews.

Type 2 Diabetes Management in Primary Care

Type 2 diabetes is one of the most resource-intensive LTCs. National audits suggest that up to half of patients do not receive all nine NICE care processes consistently, which increases the risk of cardiovascular, renal, and metabolic complications.

Clinical Pharmacists follow NICE NG28 to optimise HbA1c control, initiate and titrate SGLT2 inhibitors or GLP-1 receptor agonists, and ensure appropriate cardio-renal protection. They take a structured, data-driven approach that enables timely intervention for uncontrolled diabetes.

Pharmacy Technicians strengthen this work by managing recall lists, validating missing care processes, supporting lifestyle follow-up, and ensuring results are coded correctly. This blended model aligns with the NHS Type 2 Diabetespathway, improves consistency across PCN practices, and increases capacity for timely monitoring.

Lipid Management and Cardiovascular Disease Prevention

Lipid disorders are central to long-term cardiovascular disease prevention. NICE NG238 outlines the requirement for initiating high-intensity statins and reviewing non-HDL cholesterol and LDL-C to assess response.

Clinical Pharmacists review cardiovascular risk factors, optimise therapy, escalate to ezetimibe or PCSK9 inhibitors when required, and support adherence. They also initiate suitable patients on simvastatin, an HMG-CoA reductase inhibitor that lowers LDL cholesterol, total cholesterol and triglycerides while increasing HDL cholesterol. By reducing cholesterol levels, simvastatin improves long-term cardiovascular outcomes, including lower rates of heart attacks and strokes.

Although simvastatin is traditionally a moderate-intensity statin, modern NICE guidance (NG238) recommends high-intensity statins such as atorvastatin 20-80 mg or rosuvastatin 10-40 mg as first-line for most patients requiring primary or secondary prevention. Clinical Pharmacists use simvastatin appropriately for patients who require a lower-intensity option, have previously stabilised on simvastatin, or cannot tolerate high-intensity alternatives.

Pharmacy Technicians reinforce the pathway by ensuring recall is timely, lipid profiles are completed at the correct intervals, and coding is accurate. This structured model improves lipid control, enhances treatment adherence, reduces long-term cardiovascular risk, and supports QOF performance.

Further patient information is available via NHS cholesterol guidance.

Asthma and COPD: Respiratory LTC Support

Respiratory long-term conditions are a significant driver of avoidable NHS workload. COPD alone accounts for more than 115,000 hospital admissions per year, with many of these exacerbations preventable through structured primary care interventions.

Clinical Pharmacists deliver COPD reviews aligned with NICE NG115. They assess symptoms using tools such as CAT or MRC scores, review exacerbation history, optimise inhaler regimens, and create personalised self-management plans. They also manage device switches, ensure appropriate use of inhaled corticosteroids, and support smoking cessation pharmacotherapy.

Pharmacy Technicians complement this work by coordinating recall, delivering inhaler technique coaching, ensuring accurate coding of CAT scores, and supporting follow-up after device changes.

Asthma care follows similar principles, aligned with NICE NG80, with a focus on inhaler technique, personalised action plans, and consistent preventer use.

A blended respiratory pathway reduces inappropriate SABA use, improves symptom control, and strengthens QOF delivery across the PCN.

Structured Medication Reviews as a Foundation for Safety

Structured Medication Reviews (SMRs) are a core safety mechanism for patients with frailty, multimorbidity, or complex polypharmacy. SMRs identify high-risk medicines, address interactions, support deprescribing, and improve adherence.

Within Core Prescribing Solutions’ Structured Medication Reviews and Medicines Optimisation service, Clinical Pharmacists lead SMRs and manage clinical risk, while Pharmacy Technicians gather medication histories, support compliance checks, and maintain accurate coding.

SMRs remain fundamental to safe LTC delivery and complement COPD, diabetes, hypertension, and lipid management.

Integrated LTC Pathways Through Clinical Pharmacists and Pharmacy Technicians

Integrated LTC pathways require a consistent model of search, stratification, recall, review, and follow-up. A blended workforce model ensures that both clinical decision-making and workflow management are delivered effectively across all practices in a PCN.

Core Prescribing Solutions’ ARRS Workforce Support service helps PCNs deploy Clinical Pharmacists and Pharmacy Technicians in a way that increases capacity, reduces GP workload, and improves control rates across all major LTCs. Standardised pathways reduce variation, enhance clinical safety, and deliver long-term value across the network.

When LTC pathways are delivered through structured, data-driven processes, supported by both Clinical Pharmacists and Pharmacy Technicians, practices see measurable improvements in control rates, safety, and capacity. This blended model provides long-term value and is essential for managing rising demand in modern primary care.

Adeem Azhar, CEO and Co-Founder of Core Prescribing Solutions

Frequently Asked Questions

Summary

LTC and long-term condition management in primary care continues to grow in complexity and scale. A blended workforce model using Clinical Pharmacists and Pharmacy Technicians supports structured pathways that strengthen safety, improve control rates, reduce GP workload, and deliver long-term value. Through evidence-led reviews, proactive recall, and consistent optimisation across COPD, diabetes, hypertension, lipids, and asthma, Core Prescribing Solutions helps practices provide high-quality LTC care at scale.